These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29985752)

  • 1. Methods for the analysis of multiple endpoints in small populations: A review.
    Ristl R; Urach S; Rosenkranz G; Posch M
    J Biopharm Stat; 2019; 29(1):1-29. PubMed ID: 29985752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of matched pair designs with two binary endpoints.
    Jiang Y; Xu J
    Stat Methods Med Res; 2017 Dec; 26(6):2526-2542. PubMed ID: 26294329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
    Hamasaki T; Evans SR; Asakura K
    J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints.
    Schüler S; Mucha A; Doherty P; Kieser M; Rauch G
    Int J Cardiol; 2014 Jul; 175(1):126-32. PubMed ID: 24861257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Links between analysis of surrogate endpoints and endogeneity.
    Ghosh D; Elliott MR; Taylor JM
    Stat Med; 2010 Dec; 29(28):2869-79. PubMed ID: 20803482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
    Sugimoto T; Sozu T; Hamasaki T; Evans SR
    Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.
    Bofill Roig M; Gómez Melis G
    Stat Med; 2019 May; 38(11):1935-1956. PubMed ID: 30637797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post hoc analyses: after the facts.
    Srinivas TR; Ho B; Kang J; Kaplan B
    Transplantation; 2015 Jan; 99(1):17-20. PubMed ID: 25525920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of endpoint shopping on power in confirmatory clinical trials.
    Wiens BL
    J Biopharm Stat; 2003 May; 13(2):229-40. PubMed ID: 12729391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
    Bloch DA; Lai TL; Su Z; Tubert-Bitter P
    Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed.
    Daniel RM; Tsiatis AA
    Lifetime Data Anal; 2013 Oct; 19(4):513-46. PubMed ID: 23722304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How well do multiple testing methods scale up when both n and k increase?
    Westfall PH; Manage A
    J Biopharm Stat; 2011 Jul; 21(4):583-94. PubMed ID: 21516558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity adjustment for composite binary endpoints.
    Rauch G; Kieser M
    Methods Inf Med; 2012; 51(4):309-17. PubMed ID: 22525969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.